Skip to content

Psychedelic therapy showed no clear advantage over openly given antidepressants

Across depression trials, symptom improvement did not differ significantly between psychedelic therapy and traditional antidepressants given openly.

By 100HP editorialAbstract-based explanation checked

Based on the published abstract. The full paper may contain additional methods, results and limitations.

The 30-second takeaway

This abstract-based review found no clear evidence that psychedelic-assisted therapy improved depression scores more than traditional antidepressants given openly. The comparison used changes within separate trial arms, so it does not establish that the treatments are equivalent or interchangeable. It addresses a specific question about symptom improvement when treatment awareness may influence results.

Keep in mind

The analysis compared changes across separate trials. The abstract does not provide treatment durations or adverse-event results, limiting assessment of sustained benefit and safety.

THE NUMBERS, WITH CONTEXT

What researchers found

0.3 points (95% CI, -1.39 to 1.98)

Difference in depression-score improvement

17-item Hamilton Depression Rating Scale, baseline to each trial's primary endpoint; estimate favored open-label antidepressants over psychedelic therapy (P = .73).

JAMA Psychiatry, 2026 · Original source ↓

Why treatment awareness mattered

Researchers focused on whether knowing which treatment was received could influence depression outcomes. They compared psychedelic therapy with openly administered antidepressants and also examined differences between blinded and open-label trial results.

How to read the comparison

The main estimate was uncertain and compatible with differences in either direction. Open-label antidepressant trials showed greater improvement than blinded antidepressant trials; the corresponding comparison for psychedelic therapy did not reach statistical significance.

CHECK THE ORIGINAL

The original publication

Psychedelic Therapy vs Antidepressants for the Treatment of Depression Under Equal Unblinding Conditions: A Systematic Review and Meta-Analysis.

Williams ZJ, Barnett H, Szigeti B
JAMA Psychiatry · 2026

PubMed ID
41848744
Record checked

Linked publication notices

  • CommentIn

AI-assisted research and writing. This explains one selected publication; it is not a complete review of everything known. Our approach.